Loading cisplatin onto 6-mercaptopurine covalently modified MSNS: a nanomedicine strategy to improve the outcome of cisplatin therapy

References

• WangDLippardSJCellular processing of platinum anticancer drugsNat Rev Drug Discov20054430732015789122
   PubMed Web of Science ®Google Scholar
• BaiMYLiuSZA simple and general method for preparing antibody-PEG-PLGA sub-micron particles using electrospray technique: an in vitro study of targeted delivery of cisplatin to ovarian cancer cellsColloids Surf B Biointerfaces201411734635324681046
   PubMed Web of Science ®Google Scholar
• TsengYYWangYCSuCHConcurrent delivery of carmustine, irinotecan, and cisplatin to the cerebral cavity using biodegradable nanofibers: in vitro and in vivo studiesColloids Surf B Biointerfaces201513425426126209775
   PubMed Web of Science ®Google Scholar
• LiuHZhangYLHanYZCharacterization and cytotoxicity studies of DPPC: M2+ novel delivery system for cisplatin thermo sensitivity liposome with improving loading efficiencyColloids Surf B Biointerfaces2015131122025938850
   PubMed Web of Science ®Google Scholar
• MessoriLMerlinoACisplatin binding to proteins: a structural perspectiveCoord Chem Rev20163156789
   Web of Science ®Google Scholar
• HoGYWoodwardNCowardJIGCisplatin versus carboplatin: comparative review of therapeutic management in solid malignanciesCrit Rev Oncol Hematol2016102374627105947
   PubMed Web of Science ®Google Scholar
• FennellDASummersYCadranelJCisplatin in the modern era: the backbone of first-line chemotherapy for non-small cell lung cancerCancer Treat Rev201644425026866673
   PubMed Web of Science ®Google Scholar
• PetrelliFDe StefaniARaspagliesiFLorussoDBarniSRadiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: a systematic review and meta-analysisGynecol Oncol201413416617124793000
   PubMed Web of Science ®Google Scholar
• DasariSTchounwouPBCisplatin in cancer therapy: molecular mechanisms of actionEur J Pharmacol201474036437825058905
   PubMed Web of Science ®Google Scholar
• YaoXPanichpisalKKurtzmanNNugentKCisplatin nephrotoxicity: a reviewAm J Med Sci2007334211512417700201
   PubMed Web of Science ®Google Scholar
• NojiriTHosodaHKimuraTProtective effects of ghrelin on cisplatin-induced nephrotoxicity in micePeptides201682859127298204
   PubMed Web of Science ®Google Scholar
• JahnukainenKEhmckeJHouMSchlattSTesticular function and fertility preservation in male cancer patientsBest Pract Res Clin Endocrinol Metab201125228730221397199
   PubMed Web of Science ®Google Scholar
• AminsharifiAHekmatiPNoorafshanAScrotal cooling to protect against cisplatin-induced spermatogenesis toxicity: preliminary outcome of an experimental controlled trialUrology201691909826845053
   PubMedGoogle Scholar
• KounisNGCervellinGLippiGCisplatin-induced bradycardia: cardiac toxicity or cardiac hypersensitivity and Kounis syndrome?Int J Cardiol201620281781826476038
   PubMed Web of Science ®Google Scholar
• CarozziVAChiorazziACantaAChemotherapy-induced peripheral neurotoxicity in immune-deficient mice: new useful ready-to-use animal modelsExp Neurol20152649210225450467
   PubMed Web of Science ®Google Scholar
• SharawyNRashedLYouakimMFEvaluation of multi-neuroprotective effects of erythropoietin usingcisplatin induced peripheral neurotoxicity modelExp Toxicol Pathol201567431532225758589
   PubMedGoogle Scholar
• MendoncLMda Silva MachadoCTeixeiraCCCde FreitasLAPde Lourdes Pires BianchiMAntunesLMGCurcumin reduces cisplatin-induced neurotoxicity in NGF-differentiated PC12 cellsNeurotoxicology20133420521123036615
   PubMed Web of Science ®Google Scholar
• WatanabeKInaiSJinnouchiKBabaSYagiTExpression of caspase-activated deoxyribo-nuclease (CAD) and caspase 3 (CPP32) in the cochlea of cisplatin (CDDP)-treated guinea pigsAuris Nasus Larynx200330321922512927282
   PubMed Web of Science ®Google Scholar
• BuffoniLDongiovanniDBaroneCFractionated dose of cisplatin (CDDP) and vinorelbine (VNB) chemotherapy for elderly patients with advanced non-small cell lung cancer: phase II trialLung Cancer200654335335717049672
   PubMed Web of Science ®Google Scholar
• MartoniAAMelottiBSperandiFHybrid (intravenous and oral) administration of vinorelbine plus cisplatinum followed by oral vinorelbine as first-line therapy of advanced non-small cell lung cancer: a phase II studyLung Cancer200860338739218160123
   PubMed Web of Science ®Google Scholar
• LiJSunKNiLWangXWangDZhangJSodium selenosulfate at an innocuous dose markedly prevents cisplatin-induced gastrointestinal toxicityToxicol Appl Pharmacol2012258337638322172630
   PubMed Web of Science ®Google Scholar
• FanKYGogineniHZaboliDComparison of acute toxicities in two primary chemoradiation regimens in the treatment of advanced head and neck squamous cell carcinomaAnn Surg Oncol20121961980198722290566
   PubMed Web of Science ®Google Scholar
• YangC-KWuC-ELiawC-CCombination of palonosetron, aprepitant, and dexamethasone as primary antiemetic prophylaxis for cisplatin-based chemotherapyBiomed J2016391606627105599
   PubMed Web of Science ®Google Scholar
• CortesiERamponiSCoronaMDecreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15Lung Cancer2001312–327127611165407
   PubMed Web of Science ®Google Scholar
• MatulonisUACamposSDuskaLGynecologic Cancer Program of Dana Farber-Harvard Cancer CenterPhase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervical cancerGynecol Oncol2006103116016416566993
   PubMed Web of Science ®Google Scholar
• MakrantonakisPZiotopoulosPAgelidouAVinorelbine and cisplatin combination in pretreated patients with advanced non-small cell lung cancer pretreated with a taxane-based regimen: a multicenter phase II studyLung Cancer2006531859016720058
   PubMed Web of Science ®Google Scholar
• NihoSKenmotsuHSekineICombination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II studyJ Thorac Oncol20138798098423774385
   PubMed Web of Science ®Google Scholar
• GeldartTChesterJCasbardASUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinomaEur Urol201567459960225465968
   PubMed Web of Science ®Google Scholar
• ChenH-MPanC-CTsaiC-MHsuW-HYangS-HYenC-CConcomitant primary lung cancer and metastatic pulmonary colorectal cancer that responded to gemcitabine/cisplatin/bevacizumab combination therapyJ Cancer Res Pract201527682
   Google Scholar
• ReckMSocinskiMALuftAThe effect of necitumumab in combination with gemcitabine plus cisplatin on tolerability and on quality of life: results from the phase 3 SQUIRE trialJ Thorac Oncol201611680881826980471
   PubMed Web of Science ®Google Scholar
• de Beaumais TiphaineAHjalgrimLLNerstingJEvaluation of a pediatric liquid formulation to improve 6-mercaptopurine therapy in childrenEur J Pharm Sci2016831726657824
   PubMed Web of Science ®Google Scholar
• YildirimATurkaydinMGaripcancBBayindirMCytotoxicity of multifunctional surfactant containing capped mesoporous silica nanoparticlesRSC Adv2016632060
   Web of Science ®Google Scholar
• MaTYLiuLYuanZYDirect synthesis of ordered mesoporous carbonsChem Soc Rev20134293977400323132523
   PubMed Web of Science ®Google Scholar
• SlowingIIVivero-EscotoJLWuCWLinVSMesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriersAdv Drug Deliv Rev200860111278128818514969
   PubMed Web of Science ®Google Scholar
• AmbrogioMWThomasCRZhaoYLZinkJIStoddartJFMechanized silica nanoparticles: a new frontier in theranostic nanomedicineAcc Chem Res2011441090391321675720
   PubMed Web of Science ®Google Scholar